Humanized tetra-specific octavalent antibody against clostridium difficile toxin A and B
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 3, 2024
Grant Date -
Jul 28, 2022
app pub date -
Jun 3, 2020
filing date -
Jun 3, 2019
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Novel, antibody-based binding agents derived from camelid VHH and human immunoglobulins are described. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. These binding agents can be used to treat or prevent primary and recurrent CDI. The binding agents include humanized VHH peptide monomers, linked groups of humanized VHH peptide monomers, humanized VHH peptide monomers joined to antibody Fc domains, and humanized VHH peptide monomers joined to IgG antibodies.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully